본문 바로가기

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

문서 유형
연구출판물 · 학술지 논문
등재
Nature IndexSCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
NEW ENGLAND JOURNAL OF MEDICINE386(4) · pp.351 · 2022
피인용
Web of Science 836Scopus 945
FWCI (Scopus)
86.96
JCR IF
JCR 2021 176.082
ISSN
0028-4793

저자

  1. Tilly, Herve제1저자교신저자Ctr Henri Becquerel, Dept Hematol, Rouen, France
  2. Morschhauser, FranckUniv Lille, Ctr Hosp Univ CHU Lille, ULR 7365 GRITA Grp Rech Sur Formes Injectables &, Lille, France
  3. Sehn, Laurie H.BC Canc, Ctr Lymphoid Canc, Vancouver, BC, Canada
  4. Friedberg, Jonathan W.Univ Rochester, Wilmot Canc Inst, Rochester, NY USA
  5. Trneny, M.Charles Univ Prague, Fac Med 1, Prague, Czech Republic
  6. Sharman, Jeff P.US Oncol Network, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
  7. Herbaux, CharlesCHU Montpellier, Montpellier, France
  8. Burke, John M.Rocky Mt Canc Ctr, Aurora, CO USA
  9. Matasar, MatthewMem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
  10. Rai, ShinyaKindai Univ, Fac Med, Dept Hematol & Rheumatol, Osaka, Japan
  11. Izutsu, KojiNatl Canc Ctr, Tokyo, Japan
  12. Mehta-Shah, NehaWashington Univ, St Louis, MO 63110 USA
  13. Oberic, LucieInst Univ Canc, Dept Hematol, Toulouse Oncopole, Toulouse, France
  14. Chauchet, AdrienCtr Hosp Reg Univ Besancon, Dept Hematol, Besancon, France
  15. Jurczak, WojciechMaria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland
  16. Song, YuqinPeking Univ Canc Hosp, Beijing, Peoples R China
  17. Greil, RichardParacelsus Med Univ, Salzburg Canc Res Inst, Med Dept 3, Ctr Clin Canc & Immunol Trials, Salzburg, Austria
  18. Mykhalska, LarysaFeofaniya Clin Hosp, Kiev, Ukraine
  19. Bergua-Burgues, Juan M.Hosp San Pedro de Alcantara, Caceres, Spain
  20. Cheung, Matthew C.Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
  21. Pinto, AntonioIRCCS, Hematol Oncol & Stem Cell Transplantat Unit, Ist Nazl Tumori, Fdn G Pascale, Naples, Italy
  22. 신호진Pusan Natl Univ, Pusan Natl Univ Hosp, Res Inst Med Sci, Dept Internal Med,Div Hematol Oncol,Sch Med, Busan, South Korea
  23. Hapgood, GregPrincess Alexandra Hosp, Brisbane, Qld, Australia
  24. Munhoz, EduardoHosp Erasto Gaertner, Curitiba, Parana, Brazil
  25. Abrisqueta, PauVall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Hematol, Barcelona, Spain
  26. Gau, Jyh-PyngTaipei Vet Gen Hosp, Taipei, Taiwan
  27. Hirata, JamieGenentech Inc, San Francisco, CA 94080 USA
  28. Jiang, YanwenGenentech Inc, San Francisco, CA 94080 USA
  29. Yan, MarkF Hoffmann La Roche, Mississauga, ON, Canada
  30. Lee, CalvinGenentech Inc, San Francisco, CA 94080 USA
저자 32명 모두 보기

초록

BACKGROUND Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured with R-CHOP. Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, which is ubiquitously expressed on the surface of malignant B cells. METHODS We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab vedotin, as compared with standard R-CHOP, in patients with previously untreated intermediate-risk or high-risk DLBCL. Patients 18 to 80 years of age were randomly assigned in a 1:1 ratio to receive six cycles of either pola-R-CHP or R-CHOP, plus two cycles of rituximab alone. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival and safety. RESULTS Overall, 879 patients underwent randomization: 440 were assigned to the pola-R-CHP group and 439 to the R-CHOP group. After a median follow-up of 28.2 months, the percentage of patients surviving without progression was significantly higher in the pola-R-CHP group than in the R-CHOP group (76.7% [95% confidence interval (CI), 72.7 to 80.8] vs. 70.2% [95% CI, 65.8 to 74.6] at 2 years; stratified hazard ratio for progression, relapse, or death, 0.73 by Cox regression; 95% CI, 0.57 to 0.95; P=0.02). Overall survival at 2 years did not differ significantly between the groups (88.7% [95% CI, 85.7 to 91.6] in the pola-R-CHP group and 88.6% [95% CI, 85.6 to 91.6] in the R-CHOP group; hazard ratio for death, 0.94; 95% CI, 0.65 to 1.37; P=0.75). The safety profile was similar in the two groups. CONCLUSIONS Among patients with previously untreated intermediate-risk or high-risk DLBCL, the risk of disease progression, relapse, or death was lower among those who received pola-R-CHP than among those who received R-CHOP.

키워드

RITUXIMAB PLUS CYCLOPHOSPHAMIDENON-HODGKIN-LYMPHOMAANTIBODY-DRUG CONJUGATEELDERLY-PATIENTSPHASE-IIIR-CHOPVINCRISTINEDOXORUBICINTRIALCHEMOTHERAPY

식별자

Scopus EID
2-s2.0-85123295133
WoS UID
000729947300001